Aytu Biopharma (AYTU) Profit After Tax (2010 - 2026)

Aytu Biopharma (AYTU) has reported Profit After Tax for 17 consecutive years, with -$5.6 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Profit After Tax fell 240.66% year-over-year to -$5.6 million in Q1 2026; TTM through Mar 2026 was -$34.7 million, a 2215.62% decrease from a year earlier, with the FY2025 full-year figure at -$14.2 million, up 10.49% from the prior year.
• Profit After Tax was -$5.6 million for Q1 2026 at Aytu Biopharma, up from -$10.6 million in the prior quarter.
• Over five years, Profit After Tax peaked at $4.0 million in Q1 2025 and troughed at -$53.3 million in Q1 2022.
• A 5-year average of -$7.7 million and a median of -$4.6 million in 2024 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax jumped 458.18% in 2024 and tumbled 1443.15% in 2025, its largest moves.
• Over 5 years, Profit After Tax stood at -$6.7 million in 2022, then soared by 96.71% to -$220000.0 in 2023, then jumped by 458.18% to $788000.0 in 2024, then plunged by 1443.15% to -$10.6 million in 2025, then surged by 46.92% to -$5.6 million in 2026.
• The last three Profit After Tax figures came in at -$5.6 million (Q1 2026), -$10.6 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.